Hurley Capital
PACB icon

Hurley Capital’s Pacific Biosciences PACB Stock Holding History

Hurley Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.05K Hold
2,976
– – ﹤0.01% 367
2026
Q2 		$5K Hold
2,976
– – ﹤0.01% 435
2026
Q1 		$3.93K Hold
2,976
– – ﹤0.01% 486
2025
Q4 		$5.56K Buy
+2,976
New +$5.72K ﹤0.01% 399

Other funds holding PACB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capricorn Fund Managers
Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bourne Lent Asset Management
Bourne Lent Asset Management Pawling, New York $293M AUM 24.01% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Carret Asset Management
Carret Asset Management New York $1.14B AUM 25.06% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Hurley Capital's PACB Position: Q3 2026 in Review

Hurley Capital held its Pacific Biosciences (PACB) position steady in Q3 2026 at 2,976 shares worth $7.05K. The position accounts for ﹤0.01% of the portfolio, ranked #367.

Hurley Capital first reported a position in PACB in Q4 2025 and has held it in 4 quarters since. 78 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Hurley Capital held 2,976 shares of Pacific Biosciences worth $7.05K as of Q3 2026.
  • Hurley Capital left its Pacific Biosciences share count unchanged in Q3 2026.
  • Pacific Biosciences made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #367 holding.
  • Hurley Capital first reported a position in Pacific Biosciences in Q4 2025 and has held it in 4 quarters since.
  • 78 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.